Nowadays, more than 850 million people worldwide suffer from kidney disease. Over the last ten years, new therapeutic options have been discovered for slowing down chronic kidney disease progression. In this book, new multidisciplinary strategies (e.g., related to nephrology, cardiology, primary care, endocrinology, etc.) for treating patients suffering from chronic kidney disease - with and without diabetes - are fully explained and detailed. This book will give the reader the opportunity to delve into the risk factors for chronic kidney disease progression and its multifactorial treatment, to analyze the classical renin-angiotensin system protection, and to examine in depth the new strategies already present on the market for delaying kidney disease progression and decreasing cardiovascular risk in patients at high risk of cardiovascular mortality. Even though in the last decade the future of people with chronic kidney has clearly improved, the implementation of already accepted renoprotective strategies and new therapies is still crucial to prevent kidney disease from progressing to its end stage.
Indice testuale
Factors beyond diabetes facilitating the development and evolution of diabetic nephropathy
Diego F. Márquez, Luis M. Ruilope
Intensified multifactorial intervention in patients with kidney disease and microalbuminuria
Clara García-Carro
Classical blockade of renin-angiotensin-aldosterone system in diabetes and non-diabetes kidney disease
Gates B. Colbert, Elissa Foster, Shilpa Sannapaneni, Louis Damian, Edgar V. Lerma
SGLT2I as a renoprotective treatment for kidney disease
Ander Vergara, Marina López, Sheila Bermejo, Irene Agraz, María José Soler
Glucagon-like peptide-1 receptor agonists for cardiorenal protection in diabetes and obesity-related kidney disease
Marco Montomoli, Alejandra Yugueros, Luis D’Marco
Finerenone and renoprotection in diabetic kidney disease
Fotini Iatridi, Marieta P. Theodorakopoulou, Olga Balafa, Alberto Ortiz, Pantelis Sarafidis
New options for treating diabetic and non-diabetic kidney disease
Beatriz Fernàndez-Fernàndez
Diego F. Márquez, Luis M. Ruilope
Intensified multifactorial intervention in patients with kidney disease and microalbuminuria
Clara García-Carro
Classical blockade of renin-angiotensin-aldosterone system in diabetes and non-diabetes kidney disease
Gates B. Colbert, Elissa Foster, Shilpa Sannapaneni, Louis Damian, Edgar V. Lerma
SGLT2I as a renoprotective treatment for kidney disease
Ander Vergara, Marina López, Sheila Bermejo, Irene Agraz, María José Soler
Glucagon-like peptide-1 receptor agonists for cardiorenal protection in diabetes and obesity-related kidney disease
Marco Montomoli, Alejandra Yugueros, Luis D’Marco
Finerenone and renoprotection in diabetic kidney disease
Fotini Iatridi, Marieta P. Theodorakopoulou, Olga Balafa, Alberto Ortiz, Pantelis Sarafidis
New options for treating diabetic and non-diabetic kidney disease
Beatriz Fernàndez-Fernàndez
